Targeted AAV gene therapy for neuroblastoma via direct capsid-antibody coupling.
The results demonstrate the feasibility of engineering AAVs with highly specific transduction properties, providing a versatile platform for targeted tumor cell suppression and advancing the development of next-generation, precision gene therapies for cancer.